Oligonucleotide- based therapeutics and in vivo functional genomics is a cutting-edge area of research and development. The discovery of RNAi by University of Massachusetts Medical School Professor Craig Mello received the Nobel Prize in 2006. RNAi and Antisense-based drugs have proven clinical efficacy and are believed to become a novel major class of therapeutic modalities. At the University of Massachusetts Medical School (UMMS), there are multiple groups whose research has reached the stage at which functional analysis of novel and advanced oligonucleotides in animal models and preclinical development is necessary. These types of studies require access to mid-scale, uniquely chemically modified oligonucleotides that have limited commercial availability and are outside the reach of academic investigators. A Shared Instrumentation Grant will allow us to purchase the equipment to support mid scale synthesis, purification and quality control of chemically modified RNA that will enable ongoing and planned animal models and preclinical studies for research supported by 11 NIH grants and multiple grants from private foundations. Specifically, we are requesting funds to purchase a GE AKTA Pilot 10 RNA synthesizer, 218 Prep HPLC and 6530 QTOF LC- MS. The acquisition of this state-of-the-art RNA synthesis capability will propel our research and translational programs and enable the development of novel RNA-based therapies, specifically for treatment of Preeclampsia, ALS (amyotrophic lateral sclerosis), HSAN (hereditary sensory and autonomic neuropathy), Huntington, IBD (inflammatory bowel disease) and other diseases.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
Biomedical Research Support Shared Instrumentation Grants (S10)
Project #
1S10OD020012-01
Application #
8826399
Study Section
Special Emphasis Panel (ZRG1-GGG-A (30))
Program Officer
Levy, Abraham
Project Start
2015-03-24
Project End
2016-03-23
Budget Start
2015-03-24
Budget End
2016-03-23
Support Year
1
Fiscal Year
2015
Total Cost
$563,141
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Biscans, Annabelle; Haraszti, Reka A; Echeverria, Dimas et al. (2018) Hydrophobicity of Lipid-Conjugated siRNAs Predicts Productive Loading to Small Extracellular Vesicles. Mol Ther 26:1520-1528
Sanchez-Ramos, Juan; Song, Shijie; Kong, Xiaoyuan et al. (2018) Chitosan-Mangafodipir nanoparticles designed for intranasal delivery of siRNA and DNA to brain. J Drug Deliv Sci Technol 43:453-460
Osborn, Maire F; Coles, Andrew H; Golebiowski, Diane et al. (2018) Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs. Mol Cancer Ther 17:1251-1258
Hassler, Matthew R; Turanov, Anton A; Alterman, Julia F et al. (2018) Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Res 46:2185-2196
Godinho, Bruno M D C; Henninger, Nils; Bouley, James et al. (2018) Transvascular Delivery of Hydrophobically Modified siRNAs: Gene Silencing in the Rat Brain upon Disruption of the Blood-Brain Barrier. Mol Ther 26:2580-2591
Turanov, Anton A; Lo, Agnes; Hassler, Matthew R et al. (2018) RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat Biotechnol :
Didiot, Marie-Cecile; Haraszti, Reka A; Aronin, Neil et al. (2018) Loading of Extracellular Vesicles with Hydrophobically Modified siRNAs. Methods Mol Biol 1740:199-214
Ly, Socheata; Navaroli, Deanna M; Didiot, Marie-Cécile et al. (2017) Visualization of self-delivering hydrophobically modified siRNA cellular internalization. Nucleic Acids Res 45:15-25
Haraszti, Reka A; Coles, Andrew; Aronin, Neil et al. (2017) Loading of Extracellular Vesicles with Chemically Stabilized Hydrophobic siRNAs for the Treatment of Disease in the Central Nervous System. Bio Protoc 7:
Haraszti, Reka A; Roux, Loic; Coles, Andrew H et al. (2017) 5?-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo. Nucleic Acids Res 45:7581-7592

Showing the most recent 10 out of 17 publications